JP2021506922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506922A5 JP2021506922A5 JP2020534482A JP2020534482A JP2021506922A5 JP 2021506922 A5 JP2021506922 A5 JP 2021506922A5 JP 2020534482 A JP2020534482 A JP 2020534482A JP 2020534482 A JP2020534482 A JP 2020534482A JP 2021506922 A5 JP2021506922 A5 JP 2021506922A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000017578 LAG3 Human genes 0.000 claims 33
- 101150030213 Lag3 gene Proteins 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 23
- 239000000872 buffer Substances 0.000 claims 19
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 15
- 229930006000 Sucrose Natural products 0.000 claims 15
- 239000005720 sucrose Substances 0.000 claims 15
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 14
- 229920000053 polysorbate 80 Polymers 0.000 claims 14
- 229940068968 polysorbate 80 Drugs 0.000 claims 14
- 239000007974 sodium acetate buffer Substances 0.000 claims 9
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical group [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims 9
- 239000000243 solution Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000008351 acetate buffer Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000008362 succinate buffer Substances 0.000 claims 4
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical group Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 3
- 239000007853 buffer solution Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 239000012931 lyophilized formulation Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical group [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711408330 | 2017-12-22 | ||
| CN201711408330.4 | 2017-12-22 | ||
| PCT/CN2018/122534 WO2019120269A1 (zh) | 2017-12-22 | 2018-12-21 | Lag-3抗体药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506922A JP2021506922A (ja) | 2021-02-22 |
| JP2021506922A5 true JP2021506922A5 (enExample) | 2021-12-23 |
Family
ID=66993121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534482A Pending JP2021506922A (ja) | 2017-12-22 | 2018-12-21 | Ｌａｇ−３抗体医薬組成物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220031842A1 (enExample) |
| EP (1) | EP3714901A4 (enExample) |
| JP (1) | JP2021506922A (enExample) |
| KR (1) | KR20200104314A (enExample) |
| CN (1) | CN111356476B (enExample) |
| AU (1) | AU2018391217A1 (enExample) |
| BR (1) | BR112020011664A2 (enExample) |
| CA (1) | CA3085656A1 (enExample) |
| RU (1) | RU2771384C2 (enExample) |
| TW (1) | TWI869334B (enExample) |
| WO (1) | WO2019120269A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
| CN110787292B (zh) * | 2020-01-06 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 一种细胞程序性死亡受体1抗体制剂及其用途 |
| CN114504642A (zh) * | 2020-11-17 | 2022-05-17 | 江苏奥赛康药业有限公司 | 一种含抗cldn18.2抗体的液体药物组合物 |
| CN114617961B (zh) * | 2020-12-10 | 2022-12-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3单克隆抗体的注射制剂 |
| WO2023040935A1 (zh) * | 2021-09-15 | 2023-03-23 | 江苏恒瑞医药股份有限公司 | 一种含抗pvrig/tigit双特异性抗体的药物组合物 |
| MX2024003936A (es) * | 2021-09-29 | 2024-06-28 | Akeso Biopharma Inc | Anticuerpo anti-lag3, composicion farmaceutica y uso. |
| CN114874324B (zh) * | 2022-05-13 | 2023-02-03 | 苏州旭光科星抗体生物科技有限公司 | 一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用 |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| CN119971023A (zh) * | 2023-11-02 | 2025-05-13 | 正大天晴(广州)医药有限公司 | 含抗lag-3抗体的药物组合物及其用途 |
| CN120754244B (zh) * | 2025-09-10 | 2025-12-12 | 江苏豪森药业集团有限公司 | 一种含抗cd19抗体的药物组合物及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110557C (zh) * | 1994-05-06 | 2003-06-04 | 古斯达威罗斯研究所 | Lag－3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2439580T5 (en) | 2003-02-28 | 2025-01-23 | Univ Johns Hopkins | T cell regulation |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| HUE049957T2 (hu) | 2013-03-15 | 2020-11-30 | Glaxosmithkline Ip Dev Ltd | Lag-3 elleni kötõfehérjék |
| KR20160070095A (ko) * | 2013-11-05 | 2016-06-17 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제 |
| JP6772062B2 (ja) * | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | 癌の免疫療法 |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| WO2015198312A1 (en) * | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CA2993177A1 (en) * | 2015-07-22 | 2017-01-26 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
| IL257798B2 (en) * | 2015-09-02 | 2024-10-01 | Immutep Sas | Antibodies against LAG-3 |
| IL262892B2 (en) * | 2016-05-18 | 2024-04-01 | Boehringer Ingelheim Int | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
| TWI757304B (zh) * | 2016-06-23 | 2022-03-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Lag-3抗體、其抗原結合片段及其醫藥用途 |
| CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
-
2018
- 2018-12-21 TW TW107146459A patent/TWI869334B/zh active
- 2018-12-21 BR BR112020011664-5A patent/BR112020011664A2/pt not_active IP Right Cessation
- 2018-12-21 RU RU2020118313A patent/RU2771384C2/ru active
- 2018-12-21 CN CN201880059038.2A patent/CN111356476B/zh active Active
- 2018-12-21 WO PCT/CN2018/122534 patent/WO2019120269A1/zh not_active Ceased
- 2018-12-21 AU AU2018391217A patent/AU2018391217A1/en not_active Abandoned
- 2018-12-21 US US16/954,176 patent/US20220031842A1/en not_active Abandoned
- 2018-12-21 CA CA3085656A patent/CA3085656A1/en active Pending
- 2018-12-21 KR KR1020207018644A patent/KR20200104314A/ko not_active Withdrawn
- 2018-12-21 JP JP2020534482A patent/JP2021506922A/ja active Pending
- 2018-12-21 EP EP18892762.8A patent/EP3714901A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506922A5 (enExample) | ||
| RU2020118313A (ru) | Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение | |
| TWI880888B (zh) | 抗體－藥物結合物之製劑及其冷凍乾燥方法 | |
| JP2016534052A5 (enExample) | ||
| US20100260766A1 (en) | Stable antibody formulations | |
| JP2022065061A (ja) | パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法 | |
| CN106999591A (zh) | 一种抗pd‑1抗体制剂及其在医药上的应用 | |
| JP4854912B2 (ja) | 癌に対する抗体 | |
| JP2021504372A5 (enExample) | ||
| US20090306348A1 (en) | Antibody Formulation | |
| BR112020015479A2 (pt) | Anticorpos anticlaudina 18.2 e usos dos mesmos | |
| EP2061510B1 (en) | Treatment and/or prevention of barrett's esophagus using anti-ephb4 antibody-containing compositions | |
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| TW200815029A (en) | Anti-IGF-1R human monoclonal antibody formulation | |
| HUE027590T2 (hu) | Calicheamicin származék-hordozó konjugátumok | |
| CN110075295A (zh) | 具有cl2a接头的抗体-sn-38免疫缀合物 | |
| US20100158919A1 (en) | Pharmaceutical Composition | |
| JP6917681B2 (ja) | 腫瘍性疾患のための治療 | |
| CN109963581A (zh) | 一种il-15蛋白复合物药物组合物及其用途 | |
| TW202130349A (zh) | Ｐｄ－１抗體聯合紫杉類化合物在製備治療三陰性乳腺癌的藥物中的用途 | |
| CN110859959A (zh) | 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途 | |
| JP2025535500A (ja) | 抗ネクチン－４抗体－薬物コンジュゲートを含む調製物及びその使用 | |
| CN111491665B (zh) | 药物组合物 | |
| TW202543673A (zh) | 抗體-藥物結合物之製劑及其冷凍乾燥方法 | |
| CN120282803A (zh) | 抗体-药物缀合物和dnmt抑制剂的组合 |